174 related articles for article (PubMed ID: 29637404)
21. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
[TBL] [Abstract][Full Text] [Related]
22. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
[TBL] [Abstract][Full Text] [Related]
23. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
[TBL] [Abstract][Full Text] [Related]
24. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.
Yoshida K; Smith B; Craggs M; Kumar R
Psychol Med; 1998 Jan; 28(1):81-91. PubMed ID: 9483685
[TBL] [Abstract][Full Text] [Related]
25. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
26. Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.
Chartier F; Rouillon F; Berggren L; Jamonneau I; Falissard B; Llorca PM
Encephale; 2017 Aug; 43(4):303-310. PubMed ID: 28709669
[TBL] [Abstract][Full Text] [Related]
27. Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia.
Teoh S; Ilett KF; Hackett LP; Kohan R
Breastfeed Med; 2011 Apr; 6(2):85-8. PubMed ID: 20925494
[TBL] [Abstract][Full Text] [Related]
28. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.
Detke HC; Zhao F; Garhyan P; Carlson J; McDonnell D
Int Clin Psychopharmacol; 2011 Jan; 26(1):35-42. PubMed ID: 20948432
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Jones B; Taylor CC; Meehan K
J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
[TBL] [Abstract][Full Text] [Related]
30. [Post-injection syndrome after depot injection of olanzapine].
Wilms EB; van der Velden MT; van Essen FH; ten Brink C
Ned Tijdschr Geneeskd; 2014; 159():A7885. PubMed ID: 25589277
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.
Heres S; Kraemer S; Bergstrom RF; Detke HC
Int Clin Psychopharmacol; 2014 Nov; 29(6):299-312. PubMed ID: 24815672
[TBL] [Abstract][Full Text] [Related]
32. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S
Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
[TBL] [Abstract][Full Text] [Related]
33. Drug safety evaluation of olanzapine pamoate.
Schöttle D; Kuhnigk O; Naber D
Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627
[TBL] [Abstract][Full Text] [Related]
34. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
[TBL] [Abstract][Full Text] [Related]
35. [Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].
Sümegi A; Kálmán J; Csekey L
Neuropsychopharmacol Hung; 2013 Jun; 15(2):105-17. PubMed ID: 23817361
[TBL] [Abstract][Full Text] [Related]
36. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.
Li A; Ji S; Yue W; Yan H; Dong F; Ruan C; Li W; Lu W; Zhang D; Wang C
BMJ Open; 2018 Aug; 8(8):e020070. PubMed ID: 30121590
[TBL] [Abstract][Full Text] [Related]
37. Long-acting risperidone: a review of its use in schizophrenia.
Harrison TS; Goa KL
CNS Drugs; 2004; 18(2):113-32. PubMed ID: 14728058
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
Samalin L; Garay R; Ameg A; Llorca PM
Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
[TBL] [Abstract][Full Text] [Related]
40. [Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics].
Alba P
Vertex; 2017 Mar; 28(132):141-144. PubMed ID: 29522636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
